Poliomyelitis: all 227 studies
Page 3 of 3. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy InfantsCompletedNCT00879827Phase 3
- Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses IntramuscularlyCompletedNCT00604058Phase 2
- Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio VaccineCompletedNCT00514059Phase 4
- A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean ChildrenCompletedNCT00514033
- Study of Mental Fatigue in Polio SurvivorsStatus unknownNCT00487487
- Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 MonthsCompletedNCT00453570Phase 3
- REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old ChildrenCompletedNCT00447525Phase 3
- Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of AgeCompletedNCT00376779Phase 2
- Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).CompletedNCT00352963Phase 3
- Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPVCompletedNCT00348387Phase 3
- Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and ToddlersCompletedNCT00343421Phase 3
- Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy InfantsCompletedNCT00320463Phase 3
- Immunogenicity and Safety of Tetraxim Versus Local DTP + IPVCompletedNCT00319852Phase 3
- Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination SchedulesCompletedNCT00316147Phase 3
- Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488CompletedNCT00307567Phase 2
- Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in InfantsCompletedNCT00287092Phase 3
- Safety of Imovax Polio in Chinese Infants and ChildrenCompletedNCT00258843Phase 3
- Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in ThailandCompletedNCT00255021Phase 4
- Immunogenicity and Safety of Pentaxim in South African InfantsCompletedNCT00254969Phase 3
- Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)CompletedNCT00160082Not applicable
- Post-marketing Safety Study of GSK Biological's Pediarix™ VaccineCompletedNCT00146835
- Pilot Study Freeze and Transport Immune CellsCompletedNCT00138268
- Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio VaccineCompletedNCT00137696Not applicable
- Pentavalent DTaP-Hep B-IPVCompletedNCT00133445Phase 2
- Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)CompletedNCT00092469Phase 3
- Brain Physiology in Polio SurvivorsCompletedNCT00080600
- Study of "Post-Polio Syndrome"CompletedNCT00001185